Class II · Moderate risk
Timolol Maleate Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
FDA Drug Recalls
316 recalls, newest first
Class II · Moderate risk
Sulfamethoxazole & Trimethoprim Oral Suspension USP
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Sufenta (Sufentanil Citrate Injection, USP)
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Sodium DIURIL
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Sodium Chloride Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Sodium Chloride Ophthalmic Ointment
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Fentanyl Citrate Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Ropivacaine Hydrochloride Injection USP
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Rifampin Capsules USP
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Rifampin Capsules USP
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Proparacaine HCl Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Promethazine HCl Oral Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Promethazine HCl & Codeine Phosphate Oral Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Prednisolone Oral Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Pilocarpine Hydrochloride Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Oxcarbazepine Oral Suspension
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Olopatadine HCl Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Olopatadine HCl Nasal Spray
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Neomycin & Polymyxin B Sulfates
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Naloxone Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Moxifloxacin HCl Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Midazolam Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Megestrol Acetate Oral Suspension
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lorazepam Oral Concentrate
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lorazepam Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.